How BPC-157 was found in human gastric juice

This is not how most peptide research begins. Most compound discovery is driven by disease models, by pharmaceutical industry priorities, by serendipitous findings in unrelated work. Sikiric's hypothesis was almost elegantly simple: the most acid-exposed tissue in the human body has survived because it produces its own protection, and that protection is findable.

What he and his colleagues identified was a class of compounds they called "body protective compounds" — BPCs — proteins isolated from human gastric juice. The naming is straightforward to the point of being almost unglamorous. These were compounds found in the body, and they appeared to be protective. BPC. Within that broader class, they isolated and characterized a specific peptide fragment — fifteen amino acids long, drawn from a larger BPC protein — and designated it BPC-157. The numbering refers to its position and characterization within the research program, not to anything structurally notable about the sequence itself. The name stuck.

The fifteen-amino-acid sequence — Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val — is small even by peptide standards. It is, in the research Sikiric's group published, a stable fragment: more resistant to degradation in the GI tract than most peptides of comparable size, which is biologically interesting given where it was found. A peptide evolved in the stomach would presumably have some resistance to the stomach's own digestive machinery. Whether this stability was designed by evolution or is coincidental is unknowable, but it has become one of the pharmacokinetic features most often cited in the research literature.

The early work from Zagreb was focused tightly on gastric ulcers. This made sense. The hypothesis was about gastric protection; the logical test was whether the isolated fragment could protect gastric tissue under challenge. The rodent studies that began emerging in the early-to-mid 1990s looked at NSAID-induced ulcers, ethanol-induced damage, stress ulcer models — the standard toolkit of gastric injury research at the time. And in those models, BPC-157 appeared to do what Sikiric had hypothesized something in gastric juice would do: it supported mucosal healing, reduced lesion area, and appeared to modulate the inflammatory response in a way that accelerated repair. The effect sizes, in the preclinical literature, were often substantial. Enough to keep the research program going for decades.

What happened over the following thirty years is its own kind of story. The Zagreb group kept publishing. Not in the highest-impact Western journals, for the most part — the work appeared in journals like the Journal of Physiology and Pharmacology, in Croatian medical literature, and eventually in a broader range of international publications as interest grew. But the research program was largely a single-institution enterprise. Sikiric's lab became, and has remained, the dominant source of BPC-157 preclinical evidence. This is an unusual situation in modern biomedical research, where findings of significance tend to attract replication attempts from independent groups. It hasn't happened here at scale. The reasons are multiple and worth sitting with.

Part of the answer is geography and language. Croatian research in the early 1990s was not particularly well-integrated into the Western pharmacological mainstream. The funding structures were different, the publication networks were different, and the research was being produced by a relatively small Eastern European institution at a time when the internet hadn't yet flattened the access gap. A compound discovered at Harvard or Johns Hopkins in 1991 would have attracted immediate replication attempts. One discovered in Zagreb moved more slowly into the broader conversation.

Part of the answer is also the nature of the compound itself. BPC-157 is a short synthetic peptide derived from a naturally occurring protein. It cannot, in its current form, be easily patented in a way that would give a pharmaceutical company the commercial incentive to fund large-scale clinical trials. The economics of drug development require the expectation of an exclusive return on investment, and orphan compounds — molecules with real preclinical data but no clear patent protection or commercial champion — tend to sit in a research purgatory. The preclinical work continues. The clinical trials don't get funded. BPC-157 has been in this purgatory for most of its existence.

This is why BPC-157 is not FDA-approved. Not because the preclinical evidence is obviously weak — by the standards of preclinical evidence, there is actually quite a lot of it, accumulated over three decades of Zagreb laboratory work — but because the path from preclinical evidence to FDA approval runs through clinical trials, and clinical trials run on money and on commercial interest. Neither has materialized for BPC-157 in the way they would need to. The FDA has not evaluated it. The compound has not entered the regulatory pipeline in a serious way. It exists, for regulatory purposes, in the space that preclinical research occupies: promising, interesting, not approved.

The research arc did broaden, though, in ways that Sikiric's original gastric hypothesis probably didn't anticipate. Once you have a molecule that appears to support tissue healing in the stomach — via angiogenesis, via growth factor signaling, via what the Zagreb group described as interactions with the nitric oxide system — the logical next question is whether those same mechanisms work elsewhere. Tendons are also poorly vascularized. Ligaments heal slowly. Bone heals, but not always completely. The same signaling pathways that the gastric mucosa uses to repair itself are present, in modified forms, throughout connective tissue. So the research followed the mechanism.

By the 2000s and 2010s, Sikiric's group was publishing on tendon transection models, muscle injury, bone repair, peripheral nerve healing, and eventually central nervous system applications. The gastric ulcer story became one chapter in a broader narrative about systemic tissue protection. Whether BPC-157 actually does what the preclinical rodent work suggests in human tissue is still an open question. The leap from a rat tendon to a human one is not trivial. The leap from any rodent model to human clinical application requires human data, and human data in this case remains largely absent. This is the honest position the research program is in today.

What the discovery story reveals, if you look at it with some distance, is how much the compounds that find their way into wellness culture are shaped by research traditions that operated far outside that culture's awareness. BPC-157 didn't enter the biohacker conversation because someone at a major pharmaceutical company funded its development. It entered because a Croatian gastroenterologist spent decades publishing preclinical work, because that work was eventually findable on PubMed, and because the internet gave a new generation of interested readers access to the primary literature. The compound's celebrity in certain online communities has essentially nothing to do with its regulatory status, its commercial history, or the institutional prestige of the laboratory that identified it.

That's a strange way for medical compounds to travel. It means the filtration between preclinical evidence and popular adoption is much weaker than the filtration that normally governs pharmaceutical development. Something with strong animal data and no human trials can become widely discussed and widely used based on the quality of the underlying hypothesis rather than on the clinical evidence that would normally precede that conversation. BPC-157 is a particularly clear example of this pattern — not the only peptide to follow this path, but the one whose origin story makes the mechanism most legible.

The question of whether a Zagreb gastroenterology lab's three decades of rodent work amounts to something clinically significant is still unresolved. The question of whether it's been taken seriously enough, given what the preclinical data does show, is probably also worth asking. Regional research traditions produce real discoveries. The stomach lining has survived hydrochloric acid for hundreds of millions of years of evolution, and asking what it uses to do that is not a trivial question. Sikiric asked it. The answer he found has had a longer half-life in public conversation than he probably expected, and whether the clinical trials eventually arrive to validate or complicate that answer is one of the more interesting open questions in the preclinical-to-clinical pipeline right now.